Russia sees decline of drug sales for first time since 2006

8 June 2016

Sales of drugs in Russia during the period of January - March of the current year fell by 10% compared to the same period of 2015, to 270.3 billion roubles ($4.09 billion), which became the worst result for the Russian pharmaceutical market since the beginning of the 2000s, according to recent data, provided by the Russian Ministry of Health.

This became the first sales’ drop for the last 10 years. In volume terms, the market also dropped by 14% to 1.18 billion packs, reports The Pharma Letter’s local correspondent.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK